OMass is an Oxford University spin-out backed by Syncona Ltd and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.
OMass’ suite of proprietary technologies enables protein targets to be interrogated in a folded native-like state thereby preserving any associated non-covalent interactions. This allows drug interactions to be captured as well as the influence of downstream interaction networks that are necessary for dictating function. In this way, the technology enables parallel observation of binding and function at unprecedented resolution.
Our strategy is to discover, develop and ultimately commercialize a pipeline of small molecule therapeutics that bring life-changing benefits to patients suffering from immunology and genetic disorders. We are also open to strategic collaborations in high value areas where we can combine our proprietary technology with a partner’s biology expertise.